Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Zyversa Therapeutics Inc (ZVSA)

$0.67 -0.03 (-4.29%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	3.20M
Revenue (ttm)	0.00
Net Income (ttm)	-9.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	133,400
Avg Vol	2,376,236
Day's Range	N/A - N/A
Shares Out	4.77M
Stochastic %K	50%
Beta	0.82
Analysts	Strong Buy
Price Target	$12.00

Company Profile

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a...

Industry: Biotechnology

Sector: Healthcare

Phone: (754) 231-1688

Website: www.zyversa.com

Address:

2200 N. Commerce Parkway, Suite 208, Weston, United States

Declanscooty Jul. 3 at 3:47 PM

$ZVSA Not going to watch this go bankrupt.

0 · Reply

InvestHack Jun. 30 at 4:21 PM

$ZVSA we may be getting delisting news today. They have Nasadaq decision in hand.

1 · Reply

Chucky91 Jun. 30 at 12:29 PM

$BFRI News out ! Ready to fly $ZVSA $ERAS $HCTI

0 · Reply

ka1954 Jun. 26 at 10:02 PM

$ZVSA any news about the delisting appeal?

0 · Reply

Ewolf17 Jun. 26 at 1:33 PM

$ZVSA

0 · Reply

Ewolf17 Jun. 26 at 1:32 PM

$ZVSA .93

0 · Reply

sonyramssen1 Jun. 26 at 1:05 PM

$ZVSA can we get this pumping

0 · Reply

Dl71174 Jun. 26 at 12:57 PM

$ZVSA very quite board

0 · Reply

BigSqueezeComing Jun. 26 at 12:26 PM

$ZVSA ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD) By ZyVersa Therapeutics | June 26, 2025, 7:55 AM

0 · Reply

stockanalysis_ Jun. 25 at 11:04 PM

After Hours Losers: $RVPH $UK $OLLI $ZVSA $KLRS View the entire list here: https://stockanalysis.com/markets/afterhours/?ref=saveontrading

0 · Reply

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)

Jun 25, 2025, 7:55 AM EDT - 12 days ago

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200

May 20, 2025, 8:52 AM EDT - 6 weeks ago

ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's Diseases

May 12, 2025, 4:35 PM EDT - 7 weeks ago

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

May 7, 2025, 7:57 AM EDT - 2 months ago

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update

Apr 29, 2025, 7:57 AM EDT - 2 months ago

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's Disease

Apr 24, 2025, 7:57 AM EDT - 2 months ago

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status

Apr 8, 2025, 7:57 AM EDT - 3 months ago

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)

Mar 27, 2025, 9:15 AM EDT - 3 months ago

ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 18, 2025, 7:57 AM EDT - 3 months ago

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

Mar 12, 2025, 7:57 AM EDT - 4 months ago

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model

Mar 6, 2025, 8:00 AM EST - 4 months ago

ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market

Mar 5, 2025, 7:52 AM EST - 4 months ago

ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes

Dec 18, 2024, 7:55 AM EST - 7 months ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco

Nov 20, 2024, 7:55 AM EST - 8 months ago

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

Nov 14, 2024, 8:10 AM EST - 8 months ago

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

Nov 5, 2024, 7:00 AM EST - 8 months ago

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

Oct 29, 2024, 7:57 AM EDT - 8 months ago

ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs

Oct 22, 2024, 7:57 AM EDT - 9 months ago

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

Oct 17, 2024, 7:50 AM EDT - 9 months ago

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

Oct 15, 2024, 7:50 AM EDT - 9 months ago

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

Oct 7, 2024, 7:55 AM EDT - 9 months ago

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

Aug 9, 2024, 4:40 PM EDT - 11 months ago

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

Aug 7, 2024, 7:50 AM EDT - 11 months ago

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

Jul 29, 2024, 7:45 AM EDT - 1 year ago

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

Jul 25, 2024, 7:57 AM EDT - 1 year ago

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

Jul 18, 2024, 11:18 AM EDT - 1 year ago

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

Jul 9, 2024, 7:57 AM EDT - 1 year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C.

May 15, 2024, 8:35 AM EDT - 1 year ago

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

May 14, 2024, 7:57 AM EDT - 1 year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention

Apr 29, 2024, 7:57 AM EDT - 1 year ago

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease

Apr 4, 2024, 7:57 AM EDT - 1 year ago

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

Mar 25, 2024, 8:17 AM EDT - 1 year ago

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 18, 2024, 7:57 AM EDT - 1 year ago

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

Mar 14, 2024, 7:57 AM EDT - 1 year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024

Feb 29, 2024, 7:57 AM EST - 1 year ago

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

Feb 28, 2024, 7:57 AM EST - 1 year ago

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

Feb 22, 2024, 7:47 AM EST - 1 year ago

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

Feb 14, 2024, 7:53 AM EST - 1 year ago

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

Feb 7, 2024, 8:02 AM EST - 1 year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones

Jan 31, 2024, 7:57 AM EST - 1 year ago

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

Jan 24, 2024, 7:57 AM EST - 1 year ago

ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer's Disease

Jan 17, 2024, 7:52 AM EST - 1 year ago

ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis

Jan 10, 2024, 8:06 AM EST - 1 year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, Featured on Benzinga All Access

Jan 4, 2024, 7:50 AM EST - 1 year ago

ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets

Jan 3, 2024, 8:07 AM EST - 1 year ago

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024

Dec 18, 2023, 8:12 AM EST - 1 year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P.

Dec 14, 2023, 7:01 AM EST - 1 year ago

ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200

Dec 7, 2023, 11:20 AM EST - 1 year ago

ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes

Dec 6, 2023, 9:00 PM EST - 1 year ago

ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering

Declanscooty Jul. 3 at 3:47 PM

$ZVSA Not going to watch this go bankrupt.

0 · Reply

InvestHack Jun. 30 at 4:21 PM

$ZVSA we may be getting delisting news today. They have Nasadaq decision in hand.

1 · Reply

Chucky91 Jun. 30 at 12:29 PM

$BFRI News out ! Ready to fly $ZVSA $ERAS $HCTI

0 · Reply

ka1954 Jun. 26 at 10:02 PM

$ZVSA any news about the delisting appeal?

0 · Reply

Ewolf17 Jun. 26 at 1:33 PM

$ZVSA

0 · Reply

Ewolf17 Jun. 26 at 1:32 PM

$ZVSA .93

0 · Reply

sonyramssen1 Jun. 26 at 1:05 PM

$ZVSA can we get this pumping

0 · Reply

Dl71174 Jun. 26 at 12:57 PM

$ZVSA very quite board

0 · Reply

BigSqueezeComing Jun. 26 at 12:26 PM

0 · Reply

stockanalysis_ Jun. 25 at 11:04 PM

After Hours Losers: $RVPH $UK $OLLI $ZVSA $KLRS View the entire list here: https://stockanalysis.com/markets/afterhours/?ref=saveontrading

0 · Reply

kolococo Jun. 25 at 6:38 PM

$ZVSA a purchase agreement up to 10 million,so if there purchase only 500k or 1 million they have fully their agreement... what a poor PR. It should have read a purchase agreement of at least...

0 · Reply